This is a preview of subscription content, log in via an institution to check access.
Notes
Funded by Pfizer Inc and Astellas Pharma, Inc.
Reference
Ramaswamy K, et al. Economic Outcomes in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Advances in Therapy : 28 Feb 2020. Available from: URL: http://dx.doi.org/10.1007/s12325-020-01260-x
Rights and permissions
About this article
Cite this article
Reduced utilisation and costs with enzalutamide vs abiraterone in prostate cancer. PharmacoEcon Outcomes News 849, 24 (2020). https://doi.org/10.1007/s40274-020-6675-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6675-y